Shares of Revance Therapeutics, Inc. (RVNC) have gained 74.1% over the past four weeks to close the last trading session at 6.58,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof10.20 indicates a potential upside of 55%. The average comprises eight short-term price targets ranging from a low of 6.60toahighof25, with a standard deviation of $6.30. While the lowest estima ...